MAP2K7 and Miyoshi myopathy: Current ongoing clinical evaluation of MEK inhibitors, alone or in combination with other agents, in MM include RO5126766 (ClinicalTrials.gov Identifier: NCT02407509, Phase I), BIBW2992 (ClinicalTrials.gov Identifier: NCT02465060, Phase II), and binimetinib (ClinicalTrials.gov Identifier: NCT02834364, Phase II), as well as Trametinib + Akt inhibitor GSK2141795 (ClinicalTrials.gov Identifier: NCT01989598, Phase II).